Amplia Therapeutics Limited is pleased to advise that we have enrolled our first patient into ACCENT, our Phase1b/2a clinical trial of our focal adhesion kinase inhibitor, AMP945 in people with pancreatic cancer .
The aim of the trial is to test the efficacy of AMP945, when dosed in combination with standard of care gemcitabine/nab-paclitaxel chemotherapy in patients with advanced pancreatic cancer.
The primary endpoint of the trial will be the Objective Response Rate (ORR) of patients to treatment.
Amplia’s CEO and Managing Director, Dr John Lambert said:
"The work we have done to date with AMP945, both in the clinic and in preclinical models of pancreatic cancer tells us that AMP945 deserves to be clinically tested in this dangerous type of cancer. We are grateful to our first patient and their family for consenting to join the trial. It is our sincere hope that addition of AMP945 to a standard of care in pancreatic cancer improves outcomes for all patients."
For more information about the ACCENT trial
Read today’s ASX release